ANAB — AnaptysBio, Inc.
Is ANAB overbought or oversold? Here is the current MarketMoodz read.
AnaptysBio, Inc. (ANAB) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $45.61. The rating moved from Strong Oversold to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$45.61
- Last changeMoved from Strong Oversold to Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
AnaptysBio, Inc. (ANAB) is a clinical-stage biotech whose valuation is driven by upcoming development milestones, partnering prospects and cash runway. With limited commercial revenue, the company remains sensitive to clinical outcomes and financing dynamics; positive readouts or strategic deals could lift the stock, while trial setbacks or the need for dilutive financing would pressure it. Given a consolidative market tone that favors larger, diversified pharma and selective growth, near-term trading is likely to be muted and catalyst-dependent.
Key factors
- Clinical-stage pipeline drives value: future clinical readouts or partner/licensing events are primary value drivers
- Limited or no commercial revenue: company economics likely dependent on cash runway, financing and milestone/license income
- Balance sheet sensitivity: burn rate and access to capital will materially affect dilution risk and near-term survival
- M&A and biotech consolidation backdrop: continued large-cap pharma acquisitive activity could create strategic interest or acquisition optionality
- Broader market tone is consolidative: risk-on but cautious flows favor large-cap pharma and selective growth, limiting speculative biotech demand
- Regulatory and development risk: clinical setbacks, safety findings, or regulatory cold receptions can sharply reprice the equity
Risks
- Clinical trial failure or negative readouts leading to sharp de-rating
- Insufficient cash runway forcing dilutive financing at unfavorable terms
- Regulatory setbacks or unexpected safety signals increasing development timelines and costs
- Weak investor appetite for small-cap biotech in a consolidative market reducing liquidity and raising volatility
- Partners not materializing or licensing deals delayed, reducing non-dilutive funding options
- Sector-wide regulatory changes or payor/pricing pressures indirectly impacting valuation and M&A dynamics
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for ANAB — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.